

Nathan J Coffey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6899613/publications.pdf>

Version: 2024-02-01

17
papers

753
citations

686830

13
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

1308
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB1R) Receptor with Reduced Lipophilicity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2374-2387.	2.9	6
2	Cholesterol as a modulator of cannabinoid receptor CB2 signaling. <i>Scientific Reports</i> , 2021, 11, 3706.	1.6	19
3	Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB ₁ R) Antagonist. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1175-1187.	2.5	29
4	CB ₁ R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome. <i>Clinical and Translational Medicine</i> , 2021, 11, e471.	1.7	16
5	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 39-56.	0.8	27
6	The key role of NLRP3 and STING in APOL1-associated podocytopathy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	66
7	Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 178-190.	1.4	16
8	Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis. <i>Cell Metabolism</i> , 2019, 29, 1320-1333.e8.	7.2	42
9	Crystal Structure of the Human Cannabinoid Receptor CB2. <i>Cell</i> , 2019, 176, 459-467.e13.	13.5	268
10	Cannabinoid δ 1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 698-708.	2.2	48
11	Synthesis of ¹³ C ₆ -labeled, dual δ 1 target inhibitor of cannabinoid δ 1 receptor (CB ₁ R) and inducible nitric oxide synthase (iNOS). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 773-779.	0.5	5
12	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 33-55.	0.8	60
13	Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB ₁ R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1126-1141.	2.9	31
14	Synthesis of ¹³ C ₆ -(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1,2,4-oxadiazole-3-carboxamide octadeuterated JD5037. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 460-465.		
15	Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice. <i>Molecular Metabolism</i> , 2017, 6, 1517-1528.	3.0	30
16	Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. <i>JCI Insight</i> , 2017, 2, .	2.3	59
17	Ephrin-A3 promotes and maintains slow muscle fiber identity during postnatal development and reinnervation. <i>Journal of Cell Biology</i> , 2015, 211, 1077-1091.	2.3	29